GlobeNewswire: OraSure Technologies, Inc. Contains the last 10 of 416 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T15:18:15ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/02/27/2836452/0/en/OraSure-Reports-Q4-23-Revenue-of-75-9-Million.html?f=22&fvtc=4&fvtv=10294OraSure Reports Q4 ‘23 Revenue of $75.9 Million2024-02-27T21:05:00Z<![CDATA[Q4 GAAP EPS of $0.27; Q4 Non-GAAP EPS of $0.22]]>https://www.globenewswire.com/news-release/2024/02/13/2828641/0/en/OraSure-to-Announce-Fourth-Quarter-2023-Financial-Results-and-Host-Earnings-Call-on-February-27th.html?f=22&fvtc=4&fvtv=10294OraSure to Announce Fourth Quarter 2023 Financial Results and Host Earnings Call on February 27th2024-02-13T21:05:00Z<![CDATA[BETHLEHEM, Pa., Feb. 13, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering fourth quarter 2023 financial results and certain business developments for 5 p.m. ET on Tuesday, Feb. 27, 2024.]]>https://www.globenewswire.com/news-release/2024/01/04/2803852/0/en/OraSure-Technologies-Inc-Secures-Strategic-Distribution-Rights-and-Invests-in-Sapphiros-a-Next-Generation-Consumer-Diagnostics-Company.html?f=22&fvtc=4&fvtv=10294OraSure Technologies, Inc. Secures Strategic Distribution Rights and Invests in Sapphiros, a Next-Generation Consumer Diagnostics Company 2024-01-04T12:05:00Z<![CDATA[The relationship expands OraSure’s innovation pipeline with access to a broad portfolio of key Sapphiros products in development.]]>https://www.globenewswire.com/news-release/2023/11/13/2779483/0/en/OraSure-to-Participate-in-Upcoming-Investor-Conferences.html?f=22&fvtc=4&fvtv=10294OraSure to Participate in Upcoming Investor Conferences2023-11-13T21:15:00Z<![CDATA[BETHLEHEM, Pa., Nov. 13, 2023 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced the company is scheduled to participate in the following investor conferences:]]>https://www.globenewswire.com/news-release/2023/11/07/2775611/0/en/OraSure-Reports-Q3-23-Revenue-of-89-2-Million-Core-Revenue-Grows-7-Year-over-Year.html?f=22&fvtc=4&fvtv=10294OraSure Reports Q3 ‘23 Revenue of $89.2 Million; Core Revenue Grows 7% Year-over-Year2023-11-07T21:05:00Z<![CDATA[Q3 GAAP EPS of $0.15; Q3 Non-GAAP EPS of $0.27]]>https://www.globenewswire.com/news-release/2023/10/23/2765108/0/en/OraSure-to-Announce-Third-Quarter-2023-Financial-Results-and-Host-Earnings-Call-on-November-7th.html?f=22&fvtc=4&fvtv=10294OraSure to Announce Third Quarter 2023 Financial Results and Host Earnings Call on November 7th2023-10-23T20:05:00Z<![CDATA[BETHLEHEM, Pa., Oct. 23, 2023 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering third quarter 2023 financial results and certain business developments for 5:00 pm ET on Tuesday, November 7, 2023.]]>https://www.globenewswire.com/news-release/2023/08/03/2718555/0/en/OraSure-Reports-Q2-23-Revenue-of-85-4-Million-Core-Revenue-Grows-3-Year-over-Year.html?f=22&fvtc=4&fvtv=10294OraSure Reports Q2 ‘23 Revenue of $85.4 Million; Core Revenue Grows 3% Year-over-Year 2023-08-03T20:05:00Z<![CDATA[InteliSwab® test revenue of $47.5 million in Q2]]>https://www.globenewswire.com/news-release/2023/07/20/2708580/0/en/OraSure-to-Announce-Second-Quarter-2023-Financial-Results-and-Host-Earnings-Call-on-August-3rd.html?f=22&fvtc=4&fvtv=10294OraSure to Announce Second Quarter 2023 Financial Results and Host Earnings Call on August 3rd2023-07-20T20:05:00Z<![CDATA[BETHLEHEM, Pa., July 20, 2023 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2023 second quarter financial results and certain business developments for 5:00 pm ET on Thursday, August 3, 2023.]]>https://www.globenewswire.com/news-release/2023/07/20/2708070/0/en/OraSure-Technologies-Elects-Robert-McMahon-to-the-Board-of-Directors.html?f=22&fvtc=4&fvtv=10294OraSure Technologies Elects Robert McMahon to the Board of Directors2023-07-20T11:05:00Z<![CDATA[BETHLEHEM, Pa., July 20, 2023 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, announced today the election of Robert W. McMahon, CMA, MBA, to the Company’s Board of Directors, effective July 31, 2023. Including McMahon, the company’s Board of Directors has seven members.]]>https://www.globenewswire.com/news-release/2023/06/13/2687638/0/en/Study-Concludes-Self-Sampling-Using-Colli-Pee-Device-for-HPV-Screening-Is-Both-Cost-Effective-and-Could-Improve-Patient-Access.html?f=22&fvtc=4&fvtv=10294Study Concludes Self-Sampling Using Colli-Pee® Device for HPV Screening Is Both Cost Effective and Could Improve Patient Access2023-06-13T20:05:00Z<![CDATA[BETHLEHEM, Pa., June 13, 2023 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and at-home diagnostic testing, as well as non-invasive self-sampling technologies and microbiome-focused biocomputational solutions, announced today that a major health economics study featuring its Colli-Pee® device has been published in the biomedical journal “BMJ Open.” This study, conducted by experts from Aquarius Population Health Limited in London and the University of Manchester, presents valuable insights into the cost-effectiveness of self-sampling for routine human papillomavirus (HPV) primary cervical cancer screening using the Colli-Pee® UCM® self-collection device.]]>